Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2023-01-25 00:00:00 ET · period of report 2023-01-23 · accession 0001209191-23-004870 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-25 | 2023-01-23 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +105.7K | 469.1K | +29% | $0 |
| D | 2023-01-25 | 2023-01-23 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +429.0K | 429.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-23 | A | A | 105,700 | $0.00 | 469,123 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. |
| 2 | Derivative | Stock Option (right to buy) | 2023-01-23 | A | A | 429,000 | $0.00 | 429,000 | D | $22.02 · — to 2033-01-22 | 429,000 Common Stock | (F2) The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. |